We protect your health through science
Investigación
Pneumococcus
Líneas de investigación
Content with Investigacion .
Neumococos
Vigilancia epidemiológica de los serotipos y genotipos que causan enfermedad neumocócica invasiva (ENI) en España. Caracterización molecular de factores de virulencia de neumococo. Identificación y caracterización de proteínas de neumococo candidatas a vacuna. Evaluación de mecanismos de evasión de la respuesta inmune en Streptococcus pneumoniae. Impacto de los biofilms bacterianos en la persistencia del tracto respiratorio. Mecanismos de cronicidad de aislados clínicos de neumococo en pacientes con enfermedad pulmonar obstructiva crónica.
Proyectos de investigación
Content with Investigacion .
1: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones en pacientes con fibrosis quística provocadas por los patógenos Pseudomonas aeruginosa y Staphylococcus aureus: CF-TREAT
Referencia: CPP2022-009574 / MPY 375/23
Agencia Financiadora: Agencia Estatal de Investigación. MICINN.
Fecha Inicio: 01/12/2023
Fecha Fin: 30/11/2026
Financiación: 238.938 Euros
Investigadores principales: Roberto Díez Martínez, José E. Yuste Lobo y Pilar García Suárez
2: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones humanas producidas por Enterococcus faecium resistente a vancomicina (ANTI‐VRE).
Ayuda CPP2021-009054 financiada por Ministerio de Ciencia e Innovación
Investigadores principales: Roberto Díez Martínez, Jose Yuste Lobo y Mirian Domenech
Periodo: 18/11/2022 - 17/11/2025
Cuantía total: 231.455 €
3: Título del proyecto: Mecanismos de virulencia en patógenos respiratorios.
Entidad financiadora: Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación (Convocatoria «Proyectos I+D+I» 2020 - Modalidades «Retos Investigación» y «Generación de Conocimiento»). Referencia: PID2020-119298RB-I00
Investigador principal: Jose Yuste Lobo
Periodo: 01/09/2021 - 30/08/2024
Cuantía total: 121.000 €
4: Título del proyecto: Efectividad de la vacuna antineumocócica conjugada 13-valente frente a la hospitalización por neumonía adquirida en la comunidad en adultos de 60 años o mayores, mediante un estudio de casos y controles modificado. Estudio CIBELES.
Investigadores principales: Jose Yuste Lobo y Ángel Gil de Miguel
Entidad financiadora: PFIZER. Referencia: MVP 249/20
Periodo: 23/02/2021 - 22/02/2025
Cuantía total: 168.000 €
5: Título del proyecto: Evolution of Invasive Pneumococcal Disease in Spain with special focus on the pathogenesis of serotypes 3, 8, 11A, 19A, 22F and 33F. Investigadores principales: Jose Yuste Lobo y Mirian Domenech.
Entidad financiadora: Merck Sharp & Dohme USA. Referencia: MVP 132/21
Período: 16/06/2021 - 15/12/2023
Cuantía total: 157.448€
6: Título del proyecto: Mecanismos de patogenicidad y protección en bacterias Gram-positivas causantes de enfermedad respiratoria y bacteriemia
Investigador principal: Jose Yuste Lobo
Entidad financiadora: MINECO. Referencia: SAF2017-83388-R
Periodo: 31/12/2017 - 30/06/2021
Cuantía total: 145.200 €
7: Título del proyecto: Characterization of susceptibility to cefditoren investigating penicillin resistant clinical isolates of Streptococcus pneumoniae.
Investigadores: Jose Yuste Lobo y Mirian Domenech Lucas
Entidad financiadora: Tedec Meiji Farma, S.A. Referencia: MVP 119/20
Periodo: 11/07/2020 – 10-07-2022
Cuantía total: 76.517 €
8: Título del proyecto: Impact of clinical isolates of serotypes 22F and 33F in the epidemiology and pathogenesis of Streptococcus pneumoniae.
Investigador principal: Jose Yuste Lobo
Entidad financiadora: Merck Sharp & Dohme España, S.A. Referencia: MVE 213/18
Periodo: 10/05/2018 - 30/05/2021
Cuantía total: 157.604 €
Publicaciones destacadas
HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study
Ryan P, Valencia J, Cuevas G; Troya J; Torres-Macho J; Muñoz-Gómez MJ, Muñoz-Rivas N, Canorea I, Vázquez-Morón S (‡), Resino S (‡ *). HIV screening and retention in care in people who use drugs in Madrid, Spain: A prospective study. Infect Dis Poverty. 2021; 10(1): 111. (A; FI= 10.49; D1, Tropical Medicine; JCR 2021). PMID: 34412695. DOI: 10.1186/s40249-021-00894-5.
PUBMEDObesity-related SNPs and weight gain following first-line antiretroviral therapy.
Berenguer J (*), Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, Roca C, González-García J, Dalmau D, Olalla J, Herrero C, Villarroya F, Domingo P, Resino S. Obesity-related SNPs and weight gain following first-line antiretroviral therapy. Clin Inf Dis. 2023; In press. (A; FI= 20.99; D1, Infectious Diseases; JCR 2021).
PUBMED DOIMild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study.
García-Broncano P, Medrano LM, Berenguer J, Brochado O, González-García J, Jiménez-Sousa MA, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Muñoz-Fernández MA, Resino S (*). Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study. J Infect 2020; 80(1):99-110. (A; FI= 6.07; Q1, Infectious Diseases; JCR 2020). PMID: 31585189. DOI: 10.1016/j.jinf.2019.09.020.
PUBMEDEvaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia
Rueda C, Puig-Asensio M, Guinea J, Almirante B, Cuenca-Estrella M, Zaragoza O; CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. Clin Microbiol Infect. 2017 Jan;23(1):49.e1-49.e8.
PUBMED DOIIdentification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp
Rossi SA, de Oliveira HC, Agreda-Mellon D, Lucio J, Mendes-Giannini MJS, García-Cambero JP, Zaragoza O. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e01921-19. PMCID: PMC7179310.
PUBMED DOIParadoxical Growth of Candida albicans in the Presence of Caspofungin Is Associated with Multiple Cell Wall Rearrangements and Decreased Virulence
Rueda C, Cuenca-Estrella M, Zaragoza O. Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence. Antimicrob Agents Chemother. 2014;58(2):1071-83. PMCID: PMC3910852.
PUBMED DOIHCV cure with direct-acting antivirals improves liver and immunological markers in HIV/HCV-coinfected patients.
Brochado-Kith O, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A (‡), Jiménez-Sousa MA (‡), Resino S (‡ *). HCV cure with direct-acting antivirals improves liver and immunological markers in HIV/HCV-coinfected patients. Front immunol. 2021; 12:723196. (A; FI= 8.79; Q1, Immunology; JCR 2021). PMID: 34497613. DOI: 10.3389/fimmu.2021.723196.
PUBMEDCryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella
Trevijano-Contador N, Herrero-Fernández I, García-Barbazán I, Scorzoni L, Rueda C, Rossi SA, García-Rodas R, Zaragoza O. Cryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella. Virulence. 2015;6(1):66-74. PMCID: PMC4603429.
PUBMED DOIThe formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses
García-Barbazán I, Trevijano-Contador N, Rueda C, de Andrés B, Pérez-Tavárez R, Herrero-Fernández I, Gaspar ML, Zaragoza O. The formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses. Cell Microbiol. 2016 Jan;18(1):111-24.
PUBMED DOIPrevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey.
• Estirado Gómez A, Justo-Gil S, Limia A, Avellón A, Arce-Arnáez A, González-Rubio R, Diaz A, Del Amo J; Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey. Sci Rep. 2018 Jan 30;8(1):1858.
PUBMED DOIComparative Analysis of Aspergillus fumigatus Strains: The Reference Genome as a Matter of Concern.
Buitrago MJ, Martín-Gómez T. Timely Diagnosis of Histoplasmosis in Non-endemic Countries: A Laboratory Challenge. Front Microbiol. 2020 Mar 24; 11:467. doi: 10.3389/fmicb.2020.00467. eCollection 2020. PMID: 32269555.
PUBMED DOIIdentification of Novel Short C-Terminal Transcripts of Human SERPINA1 Gene.
Matamala N, Aggarwal N, Iadarola P, Fumagalli M, Gomez-Mariano G, Lara B, Martinez MT, Cuesta I, Stolk J, Janciauskiene S, Martinez-Delgado B. Identification of Novel Short C-Terminal Transcripts of Human SERPINA1 Gene. PLoS One. 2017 Jan 20;12(1):e0170533.
PUBMED DOISequence Analysis of In Vivo-Expressed HIV-1 Spliced RNAs Reveals the Usage of New and Unusual Splice Sites by Viruses of Different Subtypes.
Vega Y, Delgado E, de la Barrera J, Carrera C, Zaballos Á, Cuesta I, Mariño A, Ocampo A, Miralles C, Pérez-Castro S, Álvarez H, López-Miragaya I, García-Bodas E, Díez-Fuertes F, Thomson MM. Sequence Analysis of In Vivo-Expressed HIV-1 Spliced RNAs Reveals the Usage of New and Unusual Splice Sites by Viruses of Different Subtypes. PLoS One. 2016 Jun 29;11(6):e0158525.
PUBMED DOIY155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors
Perez-Sautu U, Pozo F, Cuesta I, Monzon S, Calderon A, Gonzalez M, Molinero M, Lopez-Miragaya I, Rey S, Cañizares A, Rodriguez G, Gonzalez-Velasco C, Lackenby A, Casas I. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors. Euro Surveill. 2014 Jul 10;19(27):14-20.
PUBMED DOIComparison of two highly discriminatory typing methods to analyze Aspergillus fumigatus azole resistance
Garcia-Rubio R, Escribano P, Gomez A, Guinea J, and Mellado E. Comparison of two highly discriminatory typing methods to analyze Aspergillus fumigatus azole resistance. Frontiers in Microbiology 2018. Jul 20;9:1626.
PUBMED DOIEvaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia.
Rueda C, Puig-Asensio M, Guinea J, Almirante B, Cuenca-Estrella M, Zaragoza O. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI. Clin Microbiol Infect. 2017 Jan; 23(1):49.e1-49.e8.
PUBMED DOIDevelopment and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus.
Bernal-Martínez L, Gil H, Rivero-Menéndez O, Gago S, Cuenca-Estrella M, Mellado E, Alastruey-Izquierdo A. Development and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01083-17.
PUBMED DOICervicofacial lymphadenitis due Mycobacterium mantenii: rapid and reliable identification by MALDI-TOF MS.
Nebreda T, Andres AG, Fuentes S, Calleja R, Jimenez MS. Cervicofacial lymphadenitis due Mycobacterium mantenii: rapid and reliable identification by MALDI-TOF MS. New Microbes and New Infections .2018. March 22:1-3.
PUBMED DOIIn-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain.
Sagasta S, Millan-Lou MI, Jiménez MS, Martin C, Samper S. In-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain. Tuberculosis. 2016. Sep. 100:46-52.
PUBMED DOIGeneration and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016;60(1):6-13.
PUBMED DOICharacterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin
Garcia-Barreno B, Delgado T, Benito S, Casas I, Pozo F, Cuevas MT, et al. Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin. J Gen Virol. 2014;95(Pt 5):1033-42.
PUBMED DOIA case of respiratory toxigenic diphtheria: Contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015.
Jané, M., Vidal, M.J., Camps, N., Campins, M., Martínez, A., Balcells, J., Martin-Gomez, M.T., Bassets, G., Herrera-Leon, S., Foguet, A., Maresma, M., Follia, N., Uriona, S., Pumarola, T. A case of respiratory toxigenic diphtheria: Contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015. (2018) Eurosurveillance, 23 (13).
PUBMED DOIDevelopment of three multiplex PCR assays targeting the 21 most clinically relevant serogroups associated with Shiga toxin-producing E. coli infection in humans
Sánchez, S., Llorente, M.T., Echeita, M.A., Herrera-León, S. Development of three multiplex PCR assays targeting the 21 most clinically relevant serogroups associated with Shiga toxin-producing E. coli infection in humans (2015) PLoS ONE, 10 (1).
PUBMED DOIShiga toxin-producing Escherichia coli and atypical enteropathogenic E. coli infection in a Spanish household
Sánchez, S., Cenoz, M.G., Martín, C., Beristain, X., Llorente, M.T., Herrera-León, S. Cluster investigation of mixed O76:H19 Shiga toxin-producing Escherichia coli and atypical enteropathogenic E. coli infection in a Spanish household (2014) Epidemiology and Infection, 142 (5), pp. 1029-1033.
PUBMED DOIEpidemic history of hepatitis C virus genotypes and subtypes in Portugal.
Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Tato Marinho R, Borrego P, Taveira N. 2018. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018; 8:12266. (A; FI= 4.12; Q1 Multidisciplinary Sciences; DOI:10.1038/s41598-018-30528-0).
PUBMED DOILow frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.
Palladino C, Sanchez-Carrillo M, Mate-Cano I, Vazquez-Morón S, Jiménez-Sousa MA, Gutiérrez-Rivas M, Resino S, Briz V. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Sci Rep. 2017; 7(1):2892. (A; FI= 4.12; Q1 Multidisciplinary Sciences).
PUBMED DOIOff-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice.
Palladino C, Navarro Gomez ML, Soler-Palacin P, Gonzalez-Tome MI, Jiménez de Ory S, Espiau M, Pérez-Hoyos S, León-Leal JA, Méndez M, Moreno-Pérez D, Fortuny C, uer A, Pocheville I, Moreno S, Briz V, on behalf of the CoRISpe Working Group. Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice. AIDS 2015; 29-16, pp.2155-2159. (A; FI= 4,407; Q1 Infectious Disease).
PUBMED DOIComparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection.
Comparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection. Avellon A, Morago L, Garcia-Galera del Carmen M, Munoz M, Echevarría JM. J Med Virol. 2015 Nov;87(11):1934-9. Epub 2015 May 29.
PUBMED DOIRelative telomere length impact on mortality of COVID-19: sex differences.
Virseda-Berdices A, Concostrina-Martinez L, Martínez-González O, Blancas R, Resino S, Ryan P, De Juan C, Moreira-Escriche P, Martin-Vicente M, Brochado-Kith O, Blanca-López N, Jiménez-Sousa MA (‡,*), Fernández-Rodríguez A (‡). Relative telomere length impact on mortality of COVID-19: sex differences. J Med Virol 2023; 98 (1): e28368 (A; FI= 20.96; D1, Virology; JCR 2021).
PUBMEDActivity of host antimicrobials against multidrug resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide
García-Quintanilla, M., Pulido, M. R., Moreno-Martínez, P., Martín-Peña, R., López-Rojas, R., Pachón, J. and McConnell, M.J.* Activity of host antimicrobials against multidrug resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide. Antimicrobial Agents and Chemotherapy 2014. May;58(5):2972-5.
PUBMED DOIPlasma miRNA profile at COVID-19 onset predicts severity status and mortality.
Fernández-Pato A; Virseda-Berdices A, Ryan P; Martínez-González O, Peréz-García F, Resino S, Martin-Vicente M, Valle-Millares D, Brochado-Kith O; Blancas R; Ceballos FC; Bartolome-Sánchez S; Vidal-Alcántara EJ; Alonso-Menchén D, Blanca-López N; Ramirez Martinez-Acitores I, Rava M, Jiménez-Sousa MA (‡ *), Amanda Fernández-Rodríguez (‡ *). Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. Emerg Microbes Infect 2022; 11(1):676-688 (A; FI= 19.57; D1, Infectious Diseases; JCR 2021).
PUBMED DOIMild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study.
García-Broncano P, Medrano LM, Berenguer J, Brochado O, González-García J, Jiménez-Sousa MA, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Muñoz-Fernández MA, Resino S (*). Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study. J Infect 2020; 80(1):99-110. (A; FI= 6.07; Q1, Infectious Diseases; JCR 2020).
PUBMED DOIEfficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease
Buitrago MJ, Aguado JM, Ballen A, Bernal-Martinez L, Prieto M, Garcia-Reyne A, Garcia-Rodriguez J, Rodriguez-Tudela JL, Cuenca-Estrella M. Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease. Clin Microbiol Infect. 2013 Jun;19(6):E271-7. doi: 10.1111/1469-0691.12110. Epub 2013 Mar 7. PMID: 23464751.
PUBMED DOIAn alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains
15. Alcazar-Fuoli L, Buitrago M, Gomez-Lopez A, Mellado E. An alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains. Virulence. 2015;6(4):376-84. doi: 10.1080/21505594.2015.1025192. PMID: 26065322.
PUBMED DOINationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era
de Miguel S, Domenech M, González-Camacho F, Sempere J, Vicioso D, Sanz JC, Comas LG, Ardanuy C, Fenoll A, Yuste J. Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era. Clin Infect Dis. 2021 Dec 6;73(11):e3778-e3787
PUBMED DOIPulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis
7. Mata E, Tarancón R, Guerrero C, Moreo E, Moreau F, Uranga S, Gomez AB, Marinova D, Domenech M, Gonzalez-Camacho F, Monzon M, Badiola J, Dominguez-Andres J, Yuste J, Anel A, Peixoto A, Martin C, Aguilo N. Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis. Sci Immunol. 2021 Sep 24;6(63):eabc2934
PUBMED DOIVaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System
Corsini B, Aguinagalde L, Ruiz S, Domenech M, Yuste J. Vaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System. Vaccines. 2021 Feb 23;9(2):186.
PUBMED DOIEffect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study
Sempere J, Llamosí M, López Ruiz B, Del Río I, Pérez-García C, Lago D, Gimeno M, Coronel P, González-Camacho F, Domenech M, Yuste J. Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study. Lancet Microbe. 2022 Oct;3(10):e744-e752.
PUBMED DOIMinilungs from Human Embryonic Stem Cells to Study the Interaction of Streptococcus pneumoniae with the Respiratory Tract
Sempere J, Rossi SA, Chamorro-Herrero I, González-Camacho F, de Lucas MP, Rojas-Cabañeros JM, Taborda CP, Zaragoza Ó, Yuste J, Zambrano A. Minilungs from Human Embryonic Stem Cells to Study the Interaction of Streptococcus pneumoniae with the Respiratory Tract. Microbiol Spectr. 2022 Jun 29;10(3):e0045322
PUBMED DOISeconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains
Tirado-Vélez JM, Carreño D, Sevillano D, Alou L, Yuste J, de la Campa AG. Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains. Antibiotics. 2021 May 13;10(5):573.
PUBMED DOIA national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004-20 in Spain
Sempere J, González-Camacho F, Domenech M, Llamosí M, Del Río I, López-Ruiz B, Gimeno M, Coronel P, Yuste J. A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004-20 in Spain. J Antimicrob Chemother. 2022 Mar 31;77(4):1045-1051.
PUBMED DOIPaenibacillus spp. isolated from human and environmental samples in Spain: detection of 11 new species.
Sáez-Nieto JA, Medina-Pascual MJ, Carrasco G, Garrido N, Fernandez-Torres MA, Villalón P, Valdezate S. Paenibacillus spp. isolated from human and environmental samples in Spain: detection of 11 new species. New Microbes New Infect. 2017. 24;19:19-27.
PUBMED DOIGenomic Background and Phylogeny of cfiA-Positive Bacteroides fragilis Strains Resistant to Meropenem-EDTA
Medina-Pascual MJ, Valdezate S, Carrasco G, Villalón P, Garrido N, Saéz-Nieto JA. (2015) Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. ;21(2):150-6.
PUBMED DOIEpidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-beta-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain
Villalón P, Valdezate S, Medina-Pascual MJ, Carrasco G, Vindel A, Saez-Nieto JA. Epidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-beta-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain. J Antimicrob Chemother. 2013;68(3):550-3.
PUBMED DOIIncrease in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis.
Medina-Pascual MJ, Valdezate S, Carrasco G, Villalón P, Garrido N, Saéz-Nieto JA. (2015) Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. ;21(2):150-6
PUBMED DOIStructure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.
5. Mas V, Rodriguez L, Olmedillas E, Cano O, Palomo C, Terron MC, et al. Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. PLoS Pathog. 2016;12(9):e1005859.
PUBMED DOIEssential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations. Eur J Clin Microbiol Infect Dis. 2019 Sep
Bongomin F, Govender NP, Chakrabarti A, Robert-Gangneux F, Boulware DR, Zafar A, Oladele RO, Richardson MD, Gangneux JP, Alastruey-Izquierdo A, Bazira J, Boyles TH, Sarcarlal J, Nacher M, Obayashi T, Worodria W, Pasqualotto AC, Meya DB, Cheng B, Sriruttan C, Muzoora C, Kambugu A, Rodriguez Tudela JL, Jordan A, Chiller TM, Denning DW. Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations. Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1581-1584. doi: 10.1007/s10096-019-03600-4. PMID: 31175479.
PUBMED DOIGodet C, Alastruey-Izquierdo A, Flick H, Hennequin C, Mikilps-Mikgelbs R, Munteanu O, Page I, Seidel D, Salzer HJF. A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. J Antimicrob Chemother. 2018
Godet C, Alastruey-Izquierdo A, Flick H, Hennequin C, Mikilps-Mikgelbs R, Munteanu O, Page I, Seidel D, Salzer HJF. A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. J Antimicrob Chemother. 2018 Feb 1;73(2):280-286. doi: 10.1093/jac/dkx390. PMID: 29126309.
PUBMED DOIGenetic Characterization of Brucella spp.: Whole Genome Sequencing-Based Approach for the Determination of Multiple Locus Variable Number Tandem Repeat Profiles
Pelerito A, Nunes A, Grilo T, Isidro J, Silva C, Ferreira AC, Valdezate S, Núncio MS, Georgi E, Gomes JP. (2021) Genetic Characterization of Brucella spp.: Whole Genome Sequencing-Based Approach for the Determination of Multiple Locus Variable Number Tandem Repeat Profiles. 2021. Front Microbiol. 12;12:740068
PUBMED DOISaezia sanguinis gen. nov., sp. nov., a Betaproteobacteria member of order Burkholderiales, isolated from human blood
Medina-Pascual MJ, Monzón S, Villalón P, Cuesta I, González-Romo F, Valdezate S. (2020). Saezia sanguinis gen. nov., sp. nov., a Betaproteobacteria member of order Burkholderiales, isolated from human blood. Int J Syst Evol Microbiol.70:2016-25.
PUBMED DOIDynamics of a Sporadic Nosocomial Acinetobacter calcoaceticus-Acinetobacter baumannii Complex Population
Villalón P, Ortega M, Sáez-Nieto JA, Carrasco G, Medina-Pascual MJ, Garrido N, Valdezate S. (2019). Dynamics of a Sporadic Nosocomial Acinetobacter calcoaceticus-Acinetobacter baumannii Complex Population. 2019. Front Microbiol. 22;10:593
PUBMED DOIEpidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain.
Valdezate S, Garrido N, Carrasco G, Medina-Pascual MJ, Villalón P, Navarro AM, Saéz-Nieto JA. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. J Antimicrob Chemother. 2017;72(3):754-761.
PUBMED DOIShortcomings of the commercial MALDI-TOF MS database and use of MLSA as an arbiter in the identification of Nocardia species
Carrasco G, de Dios Caballero J, Garrido N, Valdezate S, Cantón R, Sáez-Nieto JA. Shortcomings of the commercial MALDI-TOF MS database and use of MLSA as an arbiter in the identification of Nocardia species. Front Microbiol. 2016 21;7:542.
PUBMED DOIMisdiagnosis of Babesiosis as Malaria, Equatorial Guinea, 2014.
2. Arsuaga M; González LM; Salvador Padial E; Woubshet Dinkessa A; Sevilla E; Trigo E; Puente S; Gray J; Montero E. 2018. Misdiagnosis of Babesiosis as Malaria, Equatorial Guinea, 2014. Emerging Infectious Diseases.24-8, pp.1588-1589.
PUBMED DOIContent with Investigacion .
-
Aída Úbeda Trillo
Técnico de Laboratorio
Técnico superior en laboratorio de diagnóstico clínico en 2019. Lleva vinculada a la Unidad de Neumococos desde 2023 como técnico de laboratorio contratada. Anteriormente estuvo contratada en el Servicio de Microbiología y Urgencias del Hospital Infanta Sofía de Madrid.
-
José Enrique Yuste Lobo
Científico Titular
ORCID code: 0000-0001-7996-0837
Licenciado en Farmacia en 1998 y Doctor en 2002 por la Universidad Complutense de Madrid. Realizó su tesis doctoral en el laboratorio de neumococos del Centro Nacional de Microbiología del ISCIII. Posteriormente trabajó durante 5 años en Londres, primero como Investigador Asociado en el Centre for Molecular Microbiology and Infection Biology de Imperial College hasta 2003 y luego en el Centre for Respiratory Research de University College hasta 2007. Tras esta etapa posdoctoral en Reino Unido, trabajó durante 3 años como Investigador Senior en el Centro de Investigaciones Biológicas del CSIC hasta 2010. Desde entonces trabaja como Científico Titular en la Unidad de Neumococos del CNM-ISCIII, siendo el responsable científico del laboratorio desde el año 2016. Es investigador principal del grupo CIBER de Enfermedades Respiratorias (CIBERES) CB06/06/0003 (https://www.ciberes.org/grupos/grupo-de-investigacion?id=18143)
-
Mirian Domenech Luchas
Investigadora posdoctoral
ORCID code: 0000-0002-0942-8180
Licenciada en Ciencias Biológicas en 2005 y Doctora en 2012 por la Universidad Complutense de Madrid. Realizó su tesis doctoral en el Centro de Investigaciones Biológicas del CSIC bajo la dirección del Profesor Ernesto García y la Dra. Miriam Moscoso caracterizando el biofilm neumocócico y estudiando distintos antimicrobianos para prevenir y tratar las infecciones producidas por neumococo y otros patógenos. Posteriormente ha trabajado como investigadora junior para el CIBER de Enfermedades Respiratorias y para la empresa Investigación y Proyectos Microbiológicos realizando estudios sobre biofilms de patógenos respiratorios. A finales del 2018 se incorporó a la Unidad de Neumococos del Centro Nacional Microbiología del ISCIII, donde participa en las distintas labores de investigación y referencia de la Unidad y es profesora ayudante Doctor de la Facultad de Biología de la Universidad Complutense de Madrid.
-
Julio Sempere García
Investigador Posdoctoral
ORCID code: 0000-0001-9340-6867
Graduado en Bioquímica por la Universidad Complutense de Madrid, donde posteriormente cursó estudios de Máster en Microbiología y Parasitología. Actualmente realiza el programa de doctorado en Microbiología y Parasitología. Lleva asociado a la Unidad de Neumococos desde 2017, donde realizó las prácticas extracurriculares de grado y posteriormente realizó su trabajo de fin de grado (2018) y trabajo de fin de máster (2019). En 2022 obtuvo el grado de Doctor y actualmente investiga biofilms de bacterias Gram positivas, la matriz de estos y cómo interaccionan con el sistema inmune. También trabaja en la interacción de diferentes cápsulas de Streptococcus pneumoniae con el sistema inmune y patogénesis de serotipos emergentes incluidos en las futuras vacunas antineumocócicas.
-
Erick Joan Vidal Alcántara
Ayudante de Investigación
ORCID code: 0000-0001-8946-3754
Graduado en Biología por la Universidad Complutense de Madrid, y posteriormente cursó estudios de Máster en Microbiología aplicada a salud pública e investigación en enfermedades infecciosas por la Universidad de Alcalá de Henares. Lleva vinculado a la Unidad de Neumococos desde 2022 como ayudante de investigación y es personal de plantilla.
-
Inés Pareja Cerbán
Estudiante predoctoral CIBERES
ORCID code: 0009-0006-8015-7367
Graduada en Bioquímica por la Universidad de Málaga. Es contratada predoctoral del CIBER de Enfermedades Respiratorias (CIBERES) y en nuestro grupo está realizando su Tesis Doctoral en la caracterización de factores de virulencia de aislados prevalentes así como en el estudio y caracterización de nuevos antimicrobianos frente a bacterias respiratorias.
-
Covadonga Pérez García
Contratada predoctoral FPU
ORCID code: 0000-0002-5295-6480
Graduada en Biología por la Universidad Complutense de Madrid, donde posteriormente cursó estudios de Máster en Microbiología y Parasitología. Lleva vinculada a la Unidad de Neumococos desde 2019, donde realizó las prácticas extracurriculares de grado y posteriormente realizó su trabajo de fin de grado (2020) y trabajo de fin de máster (2021). En 2022 obtuvo beca predoctoral del programa FPU y actualmente investiga mecanismos de patogenicidad y protección de serotipos emergentes de neumococo.
-
Mirella Llamosí Fornés
Contratada predoctoral
ORCID code: 0000-0002-4369-9558
Graduada en Biología por la Universidad Complutense de Madrid, donde posteriormente cursó estudios de Máster en Microbiología y Parasitología. Está realizando su Tesis Doctoral en el campo de la resistencia antibiótica así como en la búsqueda y caracterización de nuevos antimicrobianos con especial interés en lograr compuestos activos frente a infecciones producidas por biofilms.
List of staff
Información adicional
The Pneumococcus Unit is in charge of two very important aspects related to pneumococcus infections, such as epidemiological surveillance and basic and translational research of diseases caused by this pathogen. Our unit contributes to the epidemiological surveillance of invasive pneumococcal disease (IPD), characterizing the serotypes and genotypes of invasive pneumococci circulating in Spain, as well as the evolution of antibiotic resistance in this pathogen.
Identification of culture-negative samples (CSF and pleural fluids) is performed using real-time PCR. Serotyping is performed using the Dot-blot and PCR-sequencing technique. Genotyping for the study of outbreaks and characterization of clones associated with hypervirulent and/or multiresistant strains is performed using the MLST technique and the analysis of complete genomes by massive sequencing. In addition, antibiotic susceptibility is determined following the EUCAST criteria.
Our unit belongs to the IBD-labnet network of the ECDC and annually notifies all cases of IPD to the ECDC and also to the IRIS (Invasive Respiratory Infection Surveillance) network. At the level of basic and translational research, our unit is responsible for studying and characterizing different molecular mechanisms of pathogenicity and protection related to pneumococcal infection. Among the main objectives are the molecular characterization of virulence factors, the study of different vaccine candidate proteins and determining the possible impact that tobacco smoke and the formation of biofilms have on the colonization of the respiratory tract.
The Pneumococcus Unit is in charge of two very important aspects related to pneumococcus infections, such as epidemiological surveillance and basic and translational research of diseases caused by this pathogen. Our unit contributes to the epidemiological surveillance of invasive pneumococcal disease (IPD), characterizing the serotypes and genotypes of invasive pneumococci circulating in Spain, as well as the evolution of antibiotic resistance in this pathogen.
Identification of culture-negative samples (CSF and pleural fluids) is performed using real-time PCR. Serotyping is performed using the Dot-blot and PCR-sequencing technique. Genotyping for the study of outbreaks and characterization of clones associated with hypervirulent and/or multiresistant strains is performed using the MLST technique and the analysis of complete genomes by massive sequencing. In addition, antibiotic susceptibility is determined following the EUCAST criteria.
Our unit belongs to the IBD-labnet network of the ECDC and annually notifies all cases of IPD to the ECDC and also to the IRIS (Invasive Respiratory Infection Surveillance) network. At the level of basic and translational research, our unit is responsible for studying and characterizing different molecular mechanisms of pathogenicity and protection related to pneumococcal infection. Among the main objectives are the molecular characterization of virulence factors, the study of different vaccine candidate proteins and determining the possible impact that tobacco smoke and the formation of biofilms have on the colonization of the respiratory tract.